radiation therapy

Overview

Radiation therapy is a major cancer treatment modality that uses ionizing radiation to damage cellular DNA and other critical biomolecules, thereby inhibiting tumor growth and inducing cell death. Its antitumor effects are mediated both by direct DNA damage and by indirect injury through reactive oxygen species generated during radiolysis. In modern oncology, radiation therapy is used as a definitive, adjuvant, neoadjuvant, or metastasis-directed treatment, often in combination with chemotherapy, surgery, targeted therapy, or immunotherapy.

Clinically, radiation therapy is central to the management of many solid tumors and selected hematologic malignancies, but its effectiveness is limited by normal-tissue toxicity and by intrinsic or acquired radioresistance. Recent research has emphasized adaptive radiotherapy, biomarker-guided treatment selection, immune modulation, and strategies to reduce complications such as radiation dermatitis, oral mucositis, pneumonitis, and ototoxicity. The field also increasingly integrates computational tools, imaging, and multi-omics approaches to optimize dose delivery and predict response.

Recent Publications Summary

Recent publications continue to position radiation therapy as a central modality across multiple Cancers while emphasizing its integration with systemic and biologically informed approaches. In a large SEER-based analysis of breast-conserving surgery for breast cancer, radiotherapy was associated with improved breast cancer-specific survival across all age groups, with age-dependent attenuation of the relative benefit and competing-risk methods used to assess absolute effects 42493682Jul. In unresectable stage III non-small cell lung cancer, a retrospective study found that induction chemoimmunotherapy followed by definitive radiotherapy and consolidation immunotherapy produced survival outcomes comparable to standard concurrent chemoradiotherapy plus consolidation immunotherapy, with similar treatment-related toxicity and a higher 3-year overall survival observed in the induction group 41200891Nov. A separate study in non-small cell lung cancer during carbon-ion radiotherapy developed a delta-based multi-omics model using clinical, dosimetric, radiomic, and dosiomic features to predict which patients would benefit from adaptive radiotherapy, highlighting the growing role of data-driven decision support in radiation planning 42031010Apr.

Several publications focused on radiation therapy as part of combination strategies intended to enhance antitumor activity or immune effects. In glioblastoma, pharmacological inhibition of UFMylation sensitized tumor cells to temozolomide and radiotherapy, while also reshaping the tumor and immune microenvironments and promoting macrophage polarization toward an anti-tumor M1 state 42472853Jul. A phase II trial protocol in resected mucosal melanoma proposed short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor, based on the rationale that radiotherapy may augment antitumor immunity and synergize with checkpoint blockade 41991257Apr. In head and neck squamous cell carcinoma, a review summarized evidence that radiation induces remodeling of the T cell landscape and alters the post-radiation tumor microenvironment in ways that may help explain why some radiotherapy and immune checkpoint inhibitor combinations have not matched preclinical expectations 41984232Apr. Broader translational efforts were also described by the Radiation Oncology-Biology Integration Network, which aims to connect omics-based biology, clinical trials, and biospecimen analysis to better understand tumor and normal tissue responses to radiation therapy 41941260Apr.

Other recent publications addressed radiation therapy in supportive care, treatment selection, and broader oncology strategy. A review of cancer therapy-induced ototoxicity identified radiotherapy among the modalities associated with cochleovestibular impairment and emphasized the need for improved monitoring and prevention strategies 41987345Apr. In lentigo maligna, a cost comparison examined radiotherapy versus topical imiquimod as non-surgical options, noting that a recent randomized trial found no difference in treatment failure, although the trial was underpowered 41421462Dec. Reviews of glioblastoma and lung cancer also noted radiotherapy as a conventional treatment whose effectiveness is limited by tumor biology and microenvironmental resistance, reinforcing the need for multimodal approaches 41944111Apr41789644Mar.

What Changes, What Holds

1. Radiotherapy remains a survival-improving backbone, but its benefit is being refined by age, competing risks, and multimodal sequencing
REINFORCES Recent work strengthens the baseline view that radiation therapy is central in solid tumors, especially when paired with systemic therapy. The breast cancer analysis supports continued use after breast-conserving surgery, while the lung cancer studies suggest the field is moving toward more individualized integration with immunotherapy and adaptive planning rather than replacing standard radiotherapy. The main change is not what radiotherapy does, but how its benefit is estimated and optimized. 42493682Jul41200891Nov42031010Apr

2. Radiation is increasingly understood as an immune- and microenvironment-modulating partner, not just a DNA-damaging cytotoxic
NEW DIRECTION The new work extends the baseline beyond direct tumor kill and ROS-mediated injury by emphasizing radiotherapy’s ability to reshape immune states, tumor microenvironments, and treatment synergy. That does not overturn the established mechanism, but it adds a clinically relevant role in combination strategies, especially where checkpoint blockade or other biologically informed agents are involved. The overview does not yet cover this immune-conditioning function as a core use. 42472853Jul41984232Apr

3. Supportive-care harms and non-surgical alternatives are becoming part of radiotherapy’s practical profile
NEW DIRECTION Recent publications add two clinically important angles that the baseline does not explicitly cover: radiotherapy as a contributor to ototoxicity risk, and radiotherapy as a non-surgical option weighed against topical therapy in lentigo maligna. These findings do not challenge the established antitumor role, but they broaden the account to include treatment-selection tradeoffs and toxicity surveillance beyond the complications already named in the overview. 41987345Apr41421462Dec

Overview update candidates: radiotherapy’s benefit may need age- and risk-adjusted interpretation in breast cancer; radiotherapy’s immune-modulating role in combination therapy; ototoxicity as a recognized supportive-care concern.